Core Viewpoint - The company, Haizheng Pharmaceutical, has successfully revoked its non-compliance statement regarding GMP for its Taizhou factory, which is expected to positively impact its product sales in the EU and other markets [1] Group 1 - On October 19, Haizheng Pharmaceutical announced the withdrawal of its non-compliance statement for its Phase II project (Y20, Y36, Y37, Y38, and Y39 buildings) [1] - The company confirmed that a search of the EU official database revealed no current non-compliance statements for its Taizhou factory [1] - The revocation of the non-compliance status by the EU is anticipated to have a positive effect on the company's product sales in the EU market and other markets [1]